J Korean Med Sci.  2017 Sep;32(9):1445-1450. 10.3346/jkms.2017.32.9.1445.

Trends in Malignancies among Korean Patients Infected with Human Immunodeficiency Virus in the Highly Active Antiretroviral Therapy Era

• Lee S
• Lee SH
• Lee JE
• Kang JS
• Lee SG
• Chung JS
• Kwak IS

• KMID: 2385950
• DOI: http://doi.org/10.3346/jkms.2017.32.9.1445

Abstract

Since the introduction of highly active antiretroviral therapy, the life span of people with human immunodeficiency virus (HIV) or AIDS (PWHA) has been extended significantly. Therefore, the importance of non-AIDS-defining cancers (NADCs), as well as AIDS-defining cancers (ADCs) has increased. There is little information concerning the epidemiology of malignancies in PWHA in Korea. A descriptive epidemiologic study was conducted at a tertiary care hospital in Korea. PWHA who visited Pusan National University Hospital from January 2000 to October 2014 were included. Demographics and clinical data were obtained from the medical records and analyzed. A total of 950 PWHA were observed for 4,439.71 person-years. Forty-eight episodes (5.05%) of cancers were diagnosed in 47 patients. Mean age of the enrolled patients was 40.66 ± 12.15 years and 88% were male. Among the 48 cancer episodes, 20 (42%) were ADCs and 28 were NADCs. The most common ADCs was non-Hodgkin's lymphoma (53.6%), followed by Kaposi's sarcoma (17.9%). The most common NADCs were lung cancer (25%) and hepatocellular carcinoma (25%). The overall incidence of total cancers, ADCs, and NADCs was 10.8 (95% confidence interval [CI], 8.0-14.3), 4.5 (95% CI, 2.8-7.0), and 6.3 (95% CI, 4.2-9.1)/1,000 person-years, respectively. NADCs accounted for 12/15 (80%) of cancers among PWHA with good adherence to care. The 5-year survival rate of PWHA and NADC was 26.3%. NADCs have become the main type of malignancy among Korean PWHA with good adherence to care. Effective strategies to improve screening of NADCs among PWHA are required in Korea.

Keyword

Malignancy; HIV; AIDS; Antiretroviral Therapy

MeSH Terms

Antiretroviral Therapy, Highly Active*
Busan
Carcinoma, Hepatocellular
Demography
Epidemiologic Studies
Epidemiology
HIV*
Humans
Humans*
Incidence
Korea
Lung Neoplasms
Lymphoma, Non-Hodgkin
Male
Mass Screening
Medical Records
Sarcoma, Kaposi
Survival Rate
Tertiary Healthcare

Reference

1. d’Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005; 165:416–423.

2. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998; 279:450–454.

3. Lee SH, Kim KH, Lee SG, Chen DH, Jung DS, Moon CS, Park JY, Chung JS, Kwak IS, Cho GJ. Trends of mortality and cause of death among HIV-infected patients in Korea, 1990–2011. J Korean Med Sci. 2013; 28:67–73.

4. Lee SH, Kim KH, Lee SG, Cho H, Chen DH, Chung JS, Kwak IS, Cho GJ. Causes of death and risk factors for mortality among HIV-infected patients receiving antiretroviral therapy in Korea. J Korean Med Sci. 2013; 28:990–997.

5. Mocroft A, Phillips AN, Friis-Møller N, Colebunders R, Johnson AM, Hirschel B, Saint-Marc T, Staub T, Clotet B, Lundgren JD, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther. 2002; 7:21–30.

6. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43:27–34.

7. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338:853–860.

8. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet. 2004; 364:69–82.

9. Chen M, Jen I, Chen YH, Lin MW, Bhatia K, Sharp GB, Law MG, Arthur Chen YM. Cancer incidence in a Nationwide HIV/AIDS patient cohort in Taiwan in 1998–2009. J Acquir Immune Defic Syndr. 2014; 65:463–472.

10. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008; 123:187–194.

11. Piketty C, Selinger-Leneman H, Bouvier AM, Belot A, Mary-Krause M, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Grabar S. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol. 2012; 30:4360–4366.

12. Polesel J, Franceschi S, Suligoi B, Crocetti E, Falcini F, Guzzinati S, Vercelli M, Zanetti R, Tagliabue G, Russo A, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer. 2010; 127:1437–1445.

13. Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2012; 118:6226–6233.

14. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000; 92:1823–1830.

15. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ; HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006; 20:1645–1654.

16. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008; 148:728–736.

17. Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, Keruly JC, Yang SC, Heitmiller RF, Baylin SB, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006; 43:47–55.

18. Mitsuyasu RT. Non--AIDS-defining malignancies in HIV. Top HIV Med. 2008; 16:117–121.

19. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Bouchardy C, Dehler S, Jundt G, Ess S, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010; 103:416–422.

20. Choe PG, Song JS, Cho JH, Kim SH, Park KH, Bang JH, Park WB, Kim HB, Kim DW, Kim TY, et al. Malignancies in patients with human immunodeficiency virus infection in South Korea. Infect Chemother. 2006; 38:367–373.

21. Seol YM, Song MG, Choi YJ, Lee SH, Kim SI, Chung JS, Kwak IS, Cho GJ, Lee H, Jung DS, et al. Trends in cancer risk among South Korean patients infected with human immunodeficiency virus. Korean J Med. 2009; 76:554–563.

22. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41:1–19.

23. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372:293–299.

24. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388:1459–1544.

25. Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014; 28:881–890.

26. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014; 384:241–248.

27. Lee HH, Hong HG, Son JS, Kwon SM, Lim BG, Lee KB, Kim GH. Prevalence of hepatitis B virus and HIV co-infection in Korea. J Bacteriol Virol. 2016; 46:283–287.

28. National Cancer Information Center of Korea. accessed on 1 December 2016. Available at www.cancer.go.kr/mbs/cancer.

29. Kang CR, Bang JH, Cho SI, Kim KN, Lee HJ, Ryu BY, Cho SK, Lee YH, Oh MD, Lee JK. Patients presenting with advanced human immunodeficiency virus disease: epidemiological features by age group. J Korean Med Sci. 2016; 31:178–182.